Compare AIFC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIFC | CGTX |
|---|---|---|
| Founded | 1976 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 79.6M |
| IPO Year | 1994 | 2021 |
| Metric | AIFC | CGTX |
|---|---|---|
| Price | $0.16 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | ★ 745.3K | 409.1K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,532,000.00 | N/A |
| Revenue This Year | $43.90 | N/A |
| Revenue Next Year | $43.25 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.55 |
| 52 Week High | $0.72 | $1.81 |
| Indicator | AIFC | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.56 | 37.17 |
| Support Level | $0.16 | $0.63 |
| Resistance Level | $0.63 | $1.18 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 4.18 | 31.67 |
AI Financial Corp is a payment infrastructure company. The company provides payment infrastructure services focused on payment processing and financial transaction technologies. Its capabilities include payment processing, security features, tokenization, and AI-based commerce solutions. It also provides infrastructure for crypto and decentralized finance (DeFi) payment processing and is developing additional capabilities for automated and programmable payment systems.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).